Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2
Cells · 26.10.2025 · 14 (21) · 1672
DOI: 10.3390/cells14211672 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 26.10.2025. Verfasst von Vivian Chetachi Eziefula Njoku und 4 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine-Qatar, Doha P.O. Box 24144, Qatar. Hauptthemen laut MEDLINE: Stomach Neoplasms, Receptor, Fibroblast Growth Factor, Type 2, Precision Medicine, Esophageal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Research Fund, National Priorities Research Program, Qatar Foundation.
Abstract (Originalsprache)
Gastric and gastroesophageal junction (G/GEJ) adenocarcinomas remain among the most aggressive and lethal malignancies globally. Most patients are diagnosed at advanced stages and respond poorly to conventional chemotherapy, highlighting the urgent demand for more effective, novel treatment strategies such as monoclonal antibody therapies targeting drivers of tumor progression. This review examines the mechanisms, safety profiles, and clinical trial outcomes of three targeted agents—bemarituzumab, zolbetuximab, and ramucirumab—which inhibit tumor growth through the FGFR2b, CLDN18.2, and VEGFR2 pathways, respectively. We also compare traditional versus adaptive clinical trial designs, explore emerging challenges such as therapeutic resistance and treatment-related toxicities, and consider implications for personalized medicine. Collectively, these agents represent a paradigm shift from empiric chemotherapy toward biomarker-driven immunotherapy, with the potential to significantly improve survival and quality of life in patients with advanced G/GEJ cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medicine-Qatar, Doha P.O. Box 24144, Qatar.
- Centre of Experimental and Clinical Regenerative Medicine, Small Animal Clinic, University of Veterinary Medicine and Pharmacy, 041 81 Kosice, Slovakia.
ORCID-Profile: Vivian Chetachi Eziefula Njoku, Yein Lee, Joytish Ramesh, Peter Kubatka, Dietrich Büsselberg
Förderung
- Qatar National Research Fund
- National Priorities Research Program
- Qatar Foundation
Zitieren
APA
Njoku, V. C. E., Lee, Y., Ramesh, J., Kubatka, P., & Büsselberg, D. (2025). Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2. Cells, 14(21), 1672. https://doi.org/10.3390/cells14211672
Vancouver
Njoku VCE, Lee Y, Ramesh J, Kubatka P, Büsselberg D. Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2. Cells. 2025;14(21):1672. doi:10.3390/cells14211672
BibTeX
@article{Njoku2025,
author = {Njoku, Vivian Chetachi Eziefula and Lee, Yein and Ramesh, Joytish and Kubatka, Peter and Büsselberg, Dietrich},
title = {Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2},
journal = {Cells},
year = {2025},
volume = {14},
number = {21},
pages = {1672},
doi = {10.3390/cells14211672}
}
EUVIMED